Conference
PCN105 Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)
Authors
Djalalov S; Beca J; Hoch JS; Krahn MD; Tsao MS; Cutz JC; Leighl N
Volume
16
Publisher
Elsevier
Publication Date
November 1, 2013
DOI
10.1016/j.jval.2013.08.503
Conference proceedings
Value in Health
Issue
7
ISSN
1098-3015